Trial Profile
Resource-effectiveness of Dalbavancin infusion as an alternative to inpatient admission for Acute Bacterial Skin and Skin Structure Infection management
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 18 Nov 2018
Price :
$35
*
At a glance
- Drugs Dalbavancin (Primary)
- Indications Bacterial infections; Skin and soft tissue infections; Skin infections
- Focus Therapeutic Use
- 18 Nov 2018 New trial record
- 07 Oct 2018 Results presented at the IDWeek 2018